Log in
NASDAQ:MYOK

MyoKardia Stock Forecast, Price & News

$224.91
0.00 (0.00 %)
(As of 11/17/2020)
Add
Compare
Today's Range
$224.91
Now: $224.91
$224.91
50-Day Range
$221.66
MA: $223.96
$224.91
52-Week Range
$42.65
Now: $224.91
$225.00
VolumeN/A
Average Volume752,969 shs
Market Capitalization$11.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
MyoKardia logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900
Employees318

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.56 million
Book Value$8.79 per share

Profitability

Net Income$-276,210,000.00

Miscellaneous

Market Cap$11.99 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$224.91
0.00 (0.00 %)
(As of 11/17/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MyoKardia (NASDAQ:MYOK) Frequently Asked Questions

How has MyoKardia's stock price been impacted by COVID-19 (Coronavirus)?

MyoKardia's stock was trading at $55.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MYOK stock has increased by 302.4% and is now trading at $224.91.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of MyoKardia?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MyoKardia in the last year. There are currently 10 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for MyoKardia
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MyoKardia?

Wall Street analysts have given MyoKardia a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MyoKardia wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MyoKardia's next earnings date?

MyoKardia is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for MyoKardia
.

How were MyoKardia's earnings last quarter?

MyoKardia, Inc. (NASDAQ:MYOK) released its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.44) by $0.16.
View MyoKardia's earnings history
.

What price target have analysts set for MYOK?

11 brokerages have issued twelve-month target prices for MyoKardia's shares. Their forecasts range from $86.00 to $225.00. On average, they expect MyoKardia's stock price to reach $207.40 in the next twelve months. This suggests that the stock has a possible downside of 7.8%.
View analysts' price targets for MyoKardia
.

Who are some of MyoKardia's key competitors?

What other stocks do shareholders of MyoKardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MyoKardia investors own include NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), CVS Health (CVS), Gilead Sciences (GILD), AbbVie (ABBV), The Walt Disney (DIS), Johnson & Johnson (JNJ), Exelixis (EXEL) and Raytheon Technologies (RTX).

Who are MyoKardia's key executives?

MyoKardia's management team includes the following people:
  • Mr. Tassos Anastasios E. Gianakakos, Pres, CEO & Director (Age 47, Pay $987.02k)
  • Mr. Taylor C. Harris, Chief Financial Officer (Age 44, Pay $604.47k)
  • Dr. Robert S. McDowell, Chief Scientific Officer (Age 62, Pay $579.19k)
  • Mr. Jake B. Bauer, Chief Bus. Officer (Age 41, Pay $547.2k)
  • Mr. William C. Fairey Jr., Chief Commercial Officer & Exec. VP (Age 54, Pay $905.02k)
  • Dr. Leslie Leinwand, Co-Founder
  • Dr. Christine E. Seidman, Co-Founder (Age 67)
  • Dr. Jonathan G. Seidman, Co-Founder
  • Dr. James A. Spudich, Co-Founder (Age 78)
  • Michelle Corral, Exec. Director of Corp. Communications & Investor Relations

What is MyoKardia's stock symbol?

MyoKardia trades on the NASDAQ under the ticker symbol "MYOK."

Who are MyoKardia's major shareholders?

MyoKardia's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.99%), State Street Corp (2.03%), Charles Schwab Investment Management Inc. (0.85%), Wells Fargo & Company MN (0.85%), JPMorgan Chase & Co. (0.80%) and Polar Capital LLP (0.78%). Company insiders that own MyoKardia stock include Anastasios Gianakakos, Cynthia J Ladd, Jake Bauer, June Lee, Mary B Cranston, Sanofi, Taylor C Harris and William Fairey.
View institutional ownership trends for MyoKardia
.

Which major investors are selling MyoKardia stock?

MYOK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Sofinnova Investments Inc., Morgan Stanley, State Street Corp, Squarepoint Ops LLC, Sphera Funds Management LTD., Cubist Systematic Strategies LLC, and Allianz Asset Management GmbH. Company insiders that have sold MyoKardia company stock in the last year include Anastasios Gianakakos, Cynthia J Ladd, Jake Bauer, Mary B Cranston, Taylor C Harris, and William Fairey.
View insider buying and selling activity for MyoKardia
.

Which major investors are buying MyoKardia stock?

MYOK stock was acquired by a variety of institutional investors in the last quarter, including Polar Capital LLP, Polar Capital LLP, JPMorgan Chase & Co., Natixis, Lord Abbett & CO. LLC, Peregrine Capital Management LLC, Charles Schwab Investment Management Inc., and Columbus Circle Investors.
View insider buying and selling activity for MyoKardia
.

How do I buy shares of MyoKardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MyoKardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $224.91.

How big of a company is MyoKardia?

MyoKardia has a market capitalization of $11.99 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-276,210,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis. MyoKardia employs 318 workers across the globe.

What is MyoKardia's official website?

The official website for MyoKardia is www.myokardia.com.

How can I contact MyoKardia?

MyoKardia's mailing address is 1000 SIERRA POINT PARKWAY, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.